Companies›Commodities›Chemicals›Chemicals & Petrochemicals

EVEXIA LIFECARE LIMITED

Chemicals › Chemicals & Petrochemicals
₹1.57
at close · 28 Oct 2026
▼ 0.08 (-4.85%)

Latest filings

  1. Newspaper publication of September quarter unaudited results · Compliance
  2. Q2 FY27 profit dips as auditor withholds review conclusion on receivables · Results
  3. Consolidated Q2 revenue and profit fall; auditor cannot conclude on results · Results
All filings ↓
Ask Nexa about EVEXIA LIFECARE LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Trades in food ingredients, edible oil and other commodities, with the bulk of disclosed segment revenue sitting in an "Others" line that is not broken out. The latest disclosed segment split (year-to-date period ending 31 December 2018) puts Others at 57.4% of segment revenue, the Food & Ingredient Division at 29.6% and Edible Oil at 13.1%, with Securities, Manufacturing and Garment divisions contributing negligible amounts. Subsidiary Kavit Edible Oil Limited has been suspended since March 2015 and carries a negative net worth. FY26 consolidated revenue was Rs. 110.275 crore with a net profit of Rs. 1.6213 crore, translating to a 2.6% EBITDA margin and a 1.47% net profit margin. Operating cash flow for FY26 was deeply negative at Rs. -2,348.34 lakhs, and the statutory auditor issued a qualified opinion flagging recoverability of Rs. 735.13 lakhs of loans and Rs. 2,943.89 lakhs of trade receivables. Cost structure as disclosed is dominated by employee cost at 1.4% of revenue and other operating expenses at 1.2% of revenue, with capex at 2.9% of revenue.

Revenue mix · reported segments
Others57.4%
Food & Ingredient Division29.6%
Edible Oil13.1%
Securities Division0.0%
Operating scale
FY26 consolidated revenue
Rs. 110.275 croreFY26
FY26 net profit
Rs. 1.6213 croreFY26
Total assets
Rs. 872.4188 croreFY26
FY26 operating cash flow
Rs. -2,348.34 lakhsFY26
Listed exchange
BSE
Suspended edible oil subsidiary
Kavit Edible Oil Limited (suspended since March 2015)
Who pays it
B2B counterparties buying traded food ingredients, edible oil and other commodities
Biggest cost
Employee cost (1.4% of revenue) and other operating expenses (1.2% of revenue), per disclosed FY26 cost shape
Kind of business
Thin-margin commodity and chemical trading company with a legacy, suspended edible oil subsidiary
Where it sits
BSE-listed small-cap classified under Trading - Chemicals, with FY26 revenue of Rs. 110.275 crore against total assets of Rs. 872.4188 crore
Market Cap
₹295 Cr
P / E (TTM)
52.3×
EV / EBITDA
88.6×
Div Yield
—
Growth
0.7%▲
Revenue 5y CAGR
PAT +4.8% · EBITDA +5.7%
Quality
0.3%·
ROCE (5y median)
ROE 0.7% (5y median) · margin 2.6%
Leverage
0.01·
Debt / Equity · low
Net debt ₹0.51 Cr
Revenue FY21→FY26
1.0×▲
Margin +0.3 pts
₹107 Cr → ₹110 Cr
Cash conversion
-2.76×▼
Operating cash ÷ profit · 5 yrs
₹-15 Cr on ₹5 Cr
Moves on a normal day
1.89%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 13 Trading - Chemicals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#12/12
P/B#5/10
ROCE#10/14
ROE#7/10
Debt / Equity#5/10
EBITDA margin#5/9
Revenue growth#4/11
Profit growth#2/10

Scorecard

Measured from the filed financials, judged against its Trading - Chemicals peers · as of FY26 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Slow revenue growth — 1% a year over 5 years
Erratic profits — up in only 2 of the last 5 years
Returns on capital 0.3% (5-year median)
#10 of 14 in Trading - Chemicals on the latest reported figures
Over 5 years it reported ₹5.46 Cr of profit and an operating cash outflow of ₹15 Cr — -2.76×
Less than 60p of every ₹1 of profit arrived as cash
Customers are taking longer to pay — 156 → 281 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from EVEXIA LIFECARE LIMITED's filed financials and exchange disclosures

What does EVEXIA LIFECARE LIMITED do?

EVEXIA LIFECARE LIMITED is a Chemicals & Petrochemicals company listed on BSE.

Is EVEXIA LIFECARE LIMITED profitable?

Yes. Over the trailing twelve months EVEXIA LIFECARE LIMITED reported a net profit of ₹2.08 Cr on revenue of ₹110 Cr.

Does EVEXIA LIFECARE LIMITED pay a dividend?

Not in the latest reported year — EVEXIA LIFECARE LIMITED's dividend payout for FY26 was nil.

Is EVEXIA LIFECARE LIMITED debt-free?

No. It reported borrowings of ₹2.89 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹0.51 Cr after cash. Debt stands at 0.01× equity. That is lower than 56% of its 10 Trading - Chemicals peers.

Is EVEXIA LIFECARE LIMITED expensive compared with its peers?

On trailing P/E, EVEXIA LIFECARE LIMITED ranks 12 of 12 in Trading - Chemicals — cheaper than 0% of them, against an industry median of 19.8×. This is a position, not a valuation judgement.

How much does the EVEXIA LIFECARE LIMITED share price move in a day?

On a typical session EVEXIA LIFECARE LIMITED moves 1.89% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track EVEXIA LIFECARE LIMITED's announcements?

Every NSE and BSE filing by EVEXIA LIFECARE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.